NCT06048224View on ClinicalTrials.gov

Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of Recombinant Anti-interleukin-6 Receptor Humanized Monoclonal Antibody Injection in Combination With Methotrexate and Jamelor ® in the Treatment of Moderate to Severe Rheumatoid Arthritis

PHASE3CompletedINTERVENTIONAL
Enrollment

669

Participants

Timeline

Start Date

December 28, 2020

Primary Completion Date

September 14, 2021

Study Completion Date

January 31, 2022

Conditions
Moderate to Severe Active Rheumatoid Arthritis
Interventions
DRUG

HS628+MTX

Participants will receive HS628 SC injections Q4W along with MTX orally for 24-week

DRUG

Actemra +MTX

Participants will receive tocilizumab SC injections Q4W along with MTX orally for 24-week

Trial Locations (1)

100730

Peking Union Medical College Hospital, Beijing

All Listed Sponsors
lead

Zhejiang Hisun Pharmaceutical Co. Ltd.

INDUSTRY

NCT06048224 - Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of Recombinant Anti-interleukin-6 Receptor Humanized Monoclonal Antibody Injection in Combination With Methotrexate and Jamelor ® in the Treatment of Moderate to Severe Rheumatoid Arthritis | Biotech Hunter | Biotech Hunter